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Introduction
 Since the mid-1980s, marked increase number of 
highly invasive group A streptococcal infections:
 With shock and organ failure
 With or without necrotizing fasciitis
“ Streptococcal toxic shock syndrome (STSS)”
 1-5 cases (up to 25 cases)/100,000 population 
annually
 30 % mortality despite appropriate treatment  
 If survival : major tissue loss, amputation of 
extremities
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True increase in both number and severity of cases
“Will these types of GAS infections 
decline, stay the same, or increase ?”
 Before the advent of antibiotics 
 Many epidemics of GAS infections : 
waxed and waned
 Changes in socioeconomic conditions ? 
 Variations in expression of virulence factors ?
 Acquisition of herd immunity to virulence factors ?
GAS epidemiology is complex
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Streptoccoccus pyogenes
Microbiological Characteristics
 Gram positive cocci
 In chains or pairs
 Growth on blood agar media
 Facultative anaerobe
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Rebecca Lancefield
Streptococcus pyogenes
 Group A antigen
 Type-specific antigen
 M protein
 > 80 M serotypes
 Fimbriae
 Major virulence factor
 Elicits protective Ab
 T protein
 Useful epidemiologic marker
 Function unknown
 Sequencing of emm gene 
encoding M protein
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Schematic location of intracellular, cellular and extracellular 
virulence factors
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Virulence factor -Biologic effect
Capsule -Antiphagocytic
M proteins -Adhesin; antiphagocytic; degrades 
complement component C3b
M-like proteins -Binds IgM, IgG and α2-macroglobulin
Protein F -Fibronectin-binding protein.Mediates 
adherence to epithelial cells
Streptolysine S -Lyses leucocytes, platelets and 
erythrocytes; stimulates release of lysosomal 
enzymes; nonimmunogenic
Streptolysine O -Lyses leucocytes, platelets and 
erythrocytes; stimulates release of lysosomal 
enzymes; immunogenic
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Virulence factor -Biologic effect
Hyaluronidase        -Hydrolyzes hyaluronic acid in deeper tissue; 
facilitates spread of infection along fascial 
planes
Streptokinase -Lyses blot clots, facilitates spread of
infection in tissue
C5a peptidase -Degrades complement component C5a
Pyrogenic exotoxins -SPE type A, B and C = erythrogenic or 
scarlatina toxins. Cause rash seen in scarlet 
fever, induce lymphocytes blastogenesis, 
potentiate endotoxin-induced shock, induce 
fever, suppress antibody synthesis and act as 
super antigen ( massive release IL, TNF)




 Carried by lysogenic phage (not all strains)
 Variation in quantity produced / decade
 Mutation, variation in potency
 SPEB
 Mediated by chromosome gene
 Variably expressed
 Severe cases of scarlet F and STSS
 SPEC
 Carried by lysogenic phage (not all strains)
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Epidemiology
 Natural reservoir
 Purely a human pathogen, skin and mucous mb.
 Relationship to humans
 Asymptomatic colonization
 Age : 15-20 % in children; <5 % in adults
 Infections
 Age : 
 most I.: incidence higher in younger (< 10 years)
 Bacteremia : neonates and elderly
 1986-1988: prevalence bacteremia  800-1000 % in 
adolescents and adults 
 Climate : 
 Pharyngitis, scarlet fever
 Impetigo
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Epidemiology
 Pharyngeal or cutaneous acquisition, person-
to-person spread via 
 Aerosolized microdroplets
 Direct contact
 In most cases of GAS infection
 Transmission and portal of entry ascertained
 Patients with STSS
 Portal of entry obvious only in 50 % of cases
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Clinical Types of Infection
 Pharyngitis and asymptomatic carriage (1-70%)
 Scarlet fever
 Erysipelas








 Postinfectious sequelae 
 Rheumatic fever, poststreptococcal glomerulonephritis
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Strep TSS - Demographic Features
 Increasing incidence of sporadic cases !
 North America and Europe
 In any age group
 Sometimes when underlying diseases
 Mostly in non immuno-compromised patients
 With Severe complications
 Bacteremia with aggressive soft tissue infection
 Shock
 Acute respiratory distress syndrome (ARDS)
 Renal failure
 Course of infection is rapid
Sharp contrasts with previous GAS bacteremia
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Strep TSS - Demographic Features
Severe complications of GAS       % of patients
soft tissue infections 
Shock 95
Acute respiratory distress syndrome-ARDS 55





Morbidity (major surgical debridment, > 65 
amputation, …)
PM -CHU Lg 09.02 18
Strep TSS - Acquisition




 IV drug abuse




Risk of secondary cases = very low, despite a high 
prevalence of « virulent strains of GAS » in population
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Strep TSS - The Clinical Picture
 PAIN
 Most common initial symptom
 Abrupt in onset
 Severe
 Usually precedes tenderness or physical findings
 Pain usually involves an extremity
 But may mimic peritonitis, pelvic inflammatory 
disease, pneumonia, acute myocardial infarction
or pericarditis
 Fever : most common presenting sign
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Strep TSS
Other symptoms and signs % of patients
Influenza like syndrome 20
Mental confusion 55
Hypotension, systolic
Soft tissue swelling 80
(necrotizing fasciitis, myositis) (70)
Endophalmitis, peritonitis, perihepatitis 20     
myocarditis, overwhelming sepsis
Diffuse scarlatina like erythema 10
Positive blood culture 69-97
Positive site of infection culture 95 
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GAS Necrotizing Fasciitis (NF)
 Deap-seated infection of subcutaneous tissue
 Progressive destruction of fascia and fat
 May spare skin and muscle
 « Streptococcal gangrene »
 Severe pain out of proportion to superficial 
appearance of skin
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GAS Necrotizing Fasciitis
 + Severe manifestation of systemic illness
 + High morbidity
 Despite antibiotics, dialysis, ventilators, IV 
fluids and improved surgical techniques
 Skin signs
 Diffuse swelling and tenderness
 Erythema, and later, bullae
 Colour change from red to purple or black
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GAS Myositis
 First, severe pain, chills and fever
 Later, swelling and erythema
 May be apparent after development of muscle 
compartment syndrome
 Differentiation with gas gangrene difficult
 Case fatality rate
 GAS NF : 20-50 % 
 GAS myositis : 80-100 % 
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GAS Bacteremia
 In the past, in very young or elderly
 Among children, predisposing factors
 Burns, varicella, immunosuppression, neoplasy, age < 2
 In older adults + elderly 
 Source = skin infection, cellulitis or erysipelas
 Diabetes, malignancy, corticosteroid use
 Rare in 14-40 years of age
 Puerperal sepsis 
 Recently
 IV drug addicts, highest prevalence of GAS Bacteremia
 In the late 1980s, 600-800% increase in 
adolescent and young adults
 Mortality: 24-26 %
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Strep TSS - The Clinical Course
 Impressive rapidity
 Progression of shock and multi-organ failure 
 Many patients may die within 24-48 h of
hospitalization
 Shock at time of admission or within 4-8 h
 Renal impairment often present at time of
admission, progression or persistance; dialysis
 If ARDS, intubation, ventilation in 90% cases 
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Strep TSS, Characteristic of
Clinical Isolates
 M types 1, 3, 6, 12 and 28 : majority of isolates
 Sweden, 80 % M-type 1 strains
 Streptococcal exotoxin type A (SPEA) and/or type 
B (SPEB) 
 SPEA in 15 % of all clinical isolates / in > 80 % of strains 
causing STSS.
 SPEA most frequently in USA / SPEB most common in 
Europe
 Streptococcal superantigen (SSA), a novel pyrogenic 
exotoxin, isolated in M-3 strains
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Strep TSS - Pathophysiology
 Why worldwide increase of severe GAS 
infections ?
 Why no epidemics ?
UNCLEAR !
 Host factors, immunity
 Same strain may cause severe invasive disease / mild 
uncomplicated disease / carrier state
 Level of Ab -M, and - SPEA
 Bacterial factors
 Change in prevalence of strains with specific virulence 
factors
PM -CHU Lg 09.02 29
Pathogenesis of Scarlet Fever, Bacteremia and S-TSS
M-1+ SPEA+ strain
Host
+ anti M1 - anti M1










- Debilitated - Children
- Compromised - Adults
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Strep TSS, Management
Surgical emergency is mandatory 
 Diagnosis should be made by surgical exploration
 IMMEDIATE aggressive surgical debridment of all
necrotic tissue
 May include amputation
 Repeated often daily
 Lesion often much more extensive / examination of
skin surface
 Spread of infection >> rate of surgery
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Strep TSS, Management
 GAS remain Sensitive to penicillin
 But reduced efficacy in severe GAS infection
 High inoculum
 Decrease in expression of Penicillin Binding Protein (PBP) by 
GAS in stationary phase
 Clindamycin more effective
 Not affected by inoculum or stationary phase
 Inhibits synthesis of bacterial toxins
 Facilitates phagocytosis of GAS by inhibiting synthesis of M 
protein
 Suppresses PBP Synthesis  degradation
 Longer post-antibiotic effect /penicillin
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Strep TSS, Management
Supportive management
 Early admission to intensive care unit
 Management for septic shock 
 Dialysis
 Tracheal intubation, mechanical ventilation
 Massive amounts of IV fluids
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Prophylaxis
 Risk of household’s contact : 
 200 times higher/general population
 CDC : no definitive recommendations
 ? Cephalosporin or macrolide : 10-day ?
 Nosocomial transmission and transmission to 
health care workers
 Appropriate precautions
 Gown, mask, gloves and meticulous handwashing
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Where do we go from here
 A wild « flesh-eating strain » has recently 
emerged
 A major epidemic would be expected
 Other GAS epidemics (pharyngitis, scarlet fever, 
rheumatic fever) occured in the past
 Last decade: incidence of GAS TSS has remained 
low
 Large outbreaks of STSS did not occur, WHY ?
PM -CHU Lg 09.02 35
Where do we go from here
Large outbreaks of STSS did not occur, WHY ?
 Vast majority of population
 Probably immunity to 1 or more virulence factors
 Predisposing conditions required in a given patient
 Varicella, use of non-steroidal anti-inflammatory drugs
 Small % of population with some other immunological 
predisposing factors
 HLA class II ag type, B cell alloantigens, or …
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What should be done ?
 Pathogenesis : more information needed
 Continued epidemiological and microbiological 
surveillance
 Improvement of therapeutic 
 Prevention strategy
 Development of M-vaccine
